Solvay S.A.
Participation Notification by Blackrock Inc.
Brussels, 11 February 2021, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay several transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves:
Date on which the threshold was crossed | Voting rights after the transaction | Equivalent financial instruments after the transaction | Total |
February 5, 2021 | 2.98% | 0.11% | 3.09% |
February 8, 2021 | 3.04% | 0.13% | 3.17% |
The latest notification, dated February 10, 2021, contains the following information:
- Reason for the notification: acquisition or disposal of voting securities or voting rights
- Notified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)
- Date on which the threshold is crossed: February 8, 2021
- Threshold of direct voting rights crossed: 3% upwards
- Denominator: 105,876,416
- Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%.
Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held is available on the Investor Relations Section of Solvay's website.
Attachments
- 20210211_transparency declaration Blackrock-EN
- Solvay_2021-02-05_Issuer_signed
- Solvay_2021-02-08_Issuer_signed
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG19.10.2025 16:30:00 CEST | Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom